The State of Innovation in Drug Development
- 1 February 2008
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 83 (2), 227-230
- https://doi.org/10.1038/sj.clpt.6100479
Abstract
The pharmaceutical industry is facing tremendous pressure, not only from payers but as a result of public perception, regulatory hurdles, and the intricacies of research and development (R&D). The latter two are significant in that they affect the number of drugs that may be registered by regulatory authorities, the time to discover and develop drugs, and the cost of drug development. Because drug development has been stagnant in terms of innovation, there exists huge potential for innovation. Failure to innovate drug development will render the "big pharma" model unsustainable.Keywords
This publication has 8 references indexed in Scilit:
- 2006 drug approvals: finding the nicheNature Reviews Drug Discovery, 2007
- The bitterest pillNature, 2006
- Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2006
- A role for fMRI in optimizing CNS drug developmentNature Reviews Drug Discovery, 2006
- Innovation and greater probability of success in drug discovery and development — from target to biomarkersCurrent Opinion in Biotechnology, 2005
- Pharmacogenetics – Where are we and Where are we Heading?Pharmacogenomics, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002